Inspirna Appoints Dr. Usman “Oz” Azam, M.D., as New Chief Executive Officer
NEW YORK--(BUSINESS WIRE)--Inspirna, Inc., a clinical stage biopharmaceutical company developing first-in-class cancer therapeutics, announced today the appointment of Dr. Usman “Oz” Azam, M.D., as its new Chief Executive Officer. Masoud Tavazoie, M.D., Ph.D., co-founder of Inspirna, recently stepped down as
Inspirna Announces Interim Data from Phase 1b/2 Study of Abequolixron (RGX-104) in Relapsed or Refractory Lung Cancer
Abequolixron in combination with docetaxel in heavily-pretreated NSCLC and SCLC is well tolerated and demonstrates encouraging preliminary clinical activity January 05, 2023 08:00 AM Eastern Standard Time NEW YORK--(BUSINESS WIRE)--Inspirna, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule cancer therapeutics,
Inspirna to Present at the Evercore ISI Annual HealthCONx Conference
November 17, 2022 08:00 AM Eastern Standard Time NEW YORK--(BUSINESS WIRE)--Inspirna, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule therapeutics, announced today that Chief Executive Officer Masoud Tavazoie, M.D., Ph.D., and Chief Operating Officer David Darst, MBA, will participate
Inspirna Raises $50 Million in Series D Financing
Funding to further support company in advancing its clinical stage oncology programs NEW YORK--(BUSINESS WIRE)--Inspirna, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule therapeutics, announced that it has raised $50 million in a Series D financing round, co-led by